Peter Strumph

Company: Parvus Therapeutics

Job title: CEO

Seminars:

Paving the Way to IND Approval: The Development of Navacims ™ & Challenges on the Way 4:45 pm

Employing Navacims™ to reprogram disease-causing T cells into disease-regulating Tregs Sharing experiences from drug development and the path to the clinic Highlighting investor and partner sentiments to accelerate the formation of relationships and investmentRead more

day: Day One